Iqvia selected to accelerate clinical development of vyvgart™ (efgartigimod alfa fcab) by argenx se

Research triangle park, n.c.--(business wire)--iqvia (nyse:iqv) announced an agreement today with argenx se. the multi-year contract covers a unique collaboration for the development of new indications for vyvgart™ (efgartigimod alfa fcab), an fda-approved neonatal fc receptor blocker for the treatment of generalized myasthenia gravis in adult patients who have a specific antibody receptor. while terms of the deal have not been disclosed, the collaboration will support clinical development, reg
IQV Ratings Summary
IQV Quant Ranking